Genmab share price logo

Genmab

NASDAQ: GMAB

Large Cap

$32.83

+0.89

(+2.77%)

as on

Genmab Stock Performance

as on August 18, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $32.28
    $32.94
    downward going graph

    1.68%

    Downside

    0.34%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $23.22
    $35.43
    downward going graph

    29.27%

    Downside

    7.92%

    Upside

    downward going graph

Genmab share price movements today

Previous Close
$31.94
Open
$32.33
Volume
4.2M
Market Cap
$19.9B
Day's Low - High
$32.28 - $32.94
52 Week Low - High
$23.22 - $35.43

Genmab Historical Returns

1 Month Return
+ 11.21 %
3 Month Return
+ 20.35 %
1 Year Return
+ 37.02 %
3 Year Return
-11.45 %
5 Year Return
-31.43 %

Genmab Stock Fundamentals & Key Indicators

Check Genmab market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$19.9B

EPS (TTM)

1.277

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.09%

PE Ratio (TTM)

24.42

Industry PE ratio

10.197

PEG Ratio

-0.28521318506853255

EBITDA

1.2B

Revenue (TTM)

4.1B

Profit Margin

39.92%

Return On Equity TTM

13.58%

Genmab Stock Valuation

Track how Genmab P/E has moved over time to understand its valuation trends.

Genmab in the last 5 years

  • Overview

  • Trends

Lowest (12.39x)

December 31, 2024

Industry (10.20x)

December 31, 2025

Today (19.91x)

December 31, 2025

Highest (57.19x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: 19.91x

Genmab vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Genmab with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$19.9B-31.43%24.4239.92%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Genmab Stock including INR - Dollar returns

The Genmab stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Genmab investment value today

Current value as on today

₹1,54,199

Returns

₹54,199

(+54.2%)

Returns from Genmab Stock

₹40,841 (+40.84%)

Dollar Impact

₹13,358 (+13.36%)

Analyst Recommendation on Genmab Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.9090909090909% of analysts recommend a 'BUY' rating for Genmab. Average target price of $38.84

Genmab Share Price Target

Get share price movements and forecasts by analysts on Genmab.

What analysts predicted

15.47%UPSIDE

Target Price

$38.84

Current Price

$32.83

Analyzed by

11 Analysts

Target

$38.84

Genmab target price $38.84, a slight upside of 15.47% compared to current price of $32.83. According to 11 analysts rating.

Indian Investors' Interest in Genmab Stock

Search interest for Genmab Stock has decreased by -66% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-66% versus previous 30 day period

Genmab Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
603
779
5,540
6,441
105
924
1,022
1,054
899
1,155
Gross Profit
576
751
5,267
6,104
99
867
964
974
834
1,071
Operating Income
116
236
2,102
2,160
27
359
459
242
225
407
EBITDA
266
324
2,204
2,355
39
447
503
98
186
431
Interest Expense
4
19
18
54
0
8
3
43
112
110
Depreciation
13
14
85
88
2
15
18
-
-
26
Income Before Tax
249
307
1,719
3,602
35
422
482
54
74
295
Income Tax Expense
57
104
453
-243
7
86
81
23
21
-8
Net Income
192
203
1,266
3,845
28
335
401
30
53
303
Net Profit Margin
95.52%
96.41%
95.07%
94.77%
94.13%
93.84%
94.32%
92.34%
92.75%
92.73%

Genmab Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2,365
3,025
5,366
10,111
8,417
14,505
16,474
21,526
3,722
Gross Profit
2,365
3,025
5,366
10,111
8,417
14,505
16,248
20,541
3,413
Operating Income
1,344
1,380
2,638
6,313
2,953
6,267
5,321
6,703
1,250
EBITDA
1,488
1,700
3,005
6,160
4,181
7,346
5,947
9,697
1,337
Interest Expense
2
0
7
10
13
21
27
120
61
Depreciation
70
87
139
246
250
362
240
413
71
Income Before Tax
1,063
1,611
2,859
5,904
3,918
6,945
5,637
9,164
1,204
Income Tax Expense
-39
139
693
1,146
961
1,493
1,285
1,320
241
Net Income
1,103
1,472
2,166
4,758
2,957
5,452
4,352
7,844
963
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
98.63%
95.42%
91.69%

Genmab Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
249
307
1,719
445
243
422
482
30
53
295
Operating Cash Flow
219
219
2,033
326
286
61
536
300
3
51
Investing Cash Flow
-210
-1,270
224
113
-42
25
-54
-5,576
-9
2
Financing Cash Flow
-85
-440
-276
40
-12
-405
-21
5,233
-177
-75
Change in Cash
-77
-1,505
2,011
425
238
-322
465
-45
-193
-18

Genmab Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
1,063
1,611
2,859
4,758
3,983
7,035
5,637
7,844
963
Operating Cash Flow
1,588
1,014
1,326
6,433
2,228
3,912
7,380
7,771
1,186
Investing Cash Flow
-667
-1,777
-1,983
-2,351
-961
-2,761
-1,282
-9,907
-5,647
Financing Cash Flow
214
-70
3,660
71
-420
-789
-606
-3,919
4,792
Change in Cash
1,040
-814
3,019
3,708
1,697
936
4,974
-5,009
345

Mutual Funds that own Genmab Stock

Check out the Mutual Funds with significant holdings in Genmab.

Funds
Holdings
Shares Held
AB LARGE CAP GROWTH FUND INC
0.296513%
1848858
Federated Hermes Equity Funds
0.139639%
870700
RUSSELL INVESTMENT CO
0.07163%
446637
Delaware Group Equity Funds IV
0.058187%
362815
Federated Hermes World Investment Series, Inc.
0.041494%
258730

Global Institutional Holdings in Genmab

Funds
Holdings
iShares
0.64%
First Trust
0.51%
James E. Flynn
0.39%
Avantis
0.09%
Invesco
0%

Genmab News & Key Events

    Insights on Genmab

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, GMAB stock has moved up by 3.5%

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 3 quarters, 30.90M → 303.00M (in $), with an average increase of 62.2% per quarter

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 2 quarters, 899.31M → 1.15B (in $), with an average increase of 22.1% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Revolution Medicines, Inc. Common Stock has given 458.9% return, outperforming this stock by 422.5%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Revolution Medicines, Inc. Common Stock has given 587.7% return, outperforming this stock by 599.7%

    About Genmab

    Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
    OrganisationGenmab
    HeadquartersCarl Jacobsens Vej 30, Copenhagen, Denmark, 2500
    IndustryBiotechnology
    CEODr. Jan G.J. van de Winkel Ph.D.
    E-voting on sharesClick here to vote

    Key Management of Genmab

    Name

    Title

    Mr. Anthony Pagano CPA

    Executive VP & CFO

    Mr. Rayne Waller

    Executive VP & Chief Technical Operations Officer

    Mr. Martin Schultz

    Senior Director, Head of Development Business Partnership & Strategy and Director

    Dr. Jan G.J. van de Winkel Ph.D.

    Co-Founder, President & CEO

    Mr. Gregory David Emil Mueller

    Executive VP, General Counsel & Chief Legal Officer

    Mr. Christopher Cozic

    Executive VP & Chief People Officer

    Dr. Martine J. van Vugt Ph.D.

    Executive VP & Chief Strategy Officer

    Dr. Judith V. Klimovsky M.D.

    Executive VP & Chief Development Officer

    Dr. Tahamtan Ahmadi M.D., Ph.D.

    Executive VP, Chief Medical Officer & Head of Experimental Medicines

    Dr. Mijke Zachariasse Ph.D.

    VP, Head of Antibody Research Materials & Director

    FAQs

    What is Genmab share price today?

    Genmab share price today is $32.83 as on at the close of the market. Genmab share today touched a day high of $32.94 and a low of $32.28.

    What is the 52 week high and 52 week low for Genmab share?

    Genmab share touched a 52 week high of $35.43 on and a 52 week low of $23.22 on . Genmab stock price today i.e. is closed at $32.83,which is 7.34% down from its 52 week high and 41.39% up from its 52 week low.

    What is Genmab's market capitalisation today?

    Genmab market capitalisation is $0.02T as on .

    How to invest in Genmab Stock (GMAB) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Genmab on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Genmab Shares that will get you 0.0457 shares as per Genmab share price of $32.83 per share as on August 18, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Genmab Stock (GMAB) from India?

    Indian investors can start investing in Genmab (GMAB) shares with as little as ₹95.592 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹955.92 in Genmab stock (as per the Rupee-Dollar exchange rate as on ). Based on Genmab share’s latest price of $32.83 as on August 18, 2026 at 1:29 am IST, you will get 0.3046 shares of Genmab. Learn more about fractional shares .

    What are the returns that Genmab has given to Indian investors in the last 5 years?

    Genmab stock has given -31.43% share price returns and 28.34% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?